Clinical trials: Optimized Treatment
Acute Myocardial Infarction, Adverse Event
Long-Term Follow-Up in Patients With Acute Myocardial Infarction Cohort
AMI Survivors who participated in the project "Construction and key technology research of the whole myocardial protection system for acute myocardial infarction" (project number 2016YFC1301100) and completed the 1-year visit…
- Trial name
- NCT05862103
- Testing
- Treatment Strategies
- Where
- 18 sites in China
- Volunteers
- 14,517 people
- Sponsor
- Yu Bo
Healthy
A Study of the Cardiac Effects of ALXN1840 in Healthy Adults
This study will evaluate the effect of a supratherapeutic dose of ALXN1840 on the heart rate (HR)-corrected QT interval (QTc) in healthy adult participants. Moxifloxacin will be used as the active control.
- Trial name
- NCT04560816
- Testing
- ALXN1840, Moxifloxacin
- Where
- United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Alexion Pharmaceuticals, Inc.
Head and Neck Cancer, Adaptive Radiotherapy
Prospective Validation of Adaptive Radiotherapy (ART) in Patients With Head and Neck Tumors
Adaptive radiotherapy (ART) includes image-guided radiotherapy (IGRT) and also offers further possibilities for plan adaptation.
- Conditions
- Head and Neck Cancer, Adaptive Radiotherapy, Radiation, Optimized Treatment
- Trial name
- ART in HNT (NCT06214611)
- Testing
- Adaptive Radiotherapy
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- University Hospital, Essen
HIV
TMC125-C216: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.
The purpose of this study is research with the goal of evaluating the effect of TMC125 (a non-nucleoside reverse transcriptase inhibitor) on slowing down the growth of the HIV virus.
- Trial name
- NCT00255099
- Testing
- TMC125
- Volunteers
- 593 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV Infections
PRINCE: Study of Atazanavir (ATV)/Ritonavir (RTV)
The purpose of this study is to determine whether atazanavir powder combined with ritonavir is safe and well tolerated and produces appropriate drug exposure in children ≥3 months to <6 years of age.
- Trial name
- PRINCE1 (NCT01099579)
- Testing
- Atazanavir powder, Ritonavir oral solution, Atazanavir capsules
- Where
- 18 sites in Brazil, Chile and 4 more
- Volunteers
- 82 people
- Sponsor
- Bristol-Myers Squibb
Colorectal Cancer
Optimized Chemotherapy Followed by Maintenance With Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Colorectal Cancer That Cannot be Removed by Surgery (DREAM)
PURPOSE: This randomized phase III trial is studying maintenance therapy with bevacizumab alone after an induction therapy combining bevacizumab+chemotherapy to see how well they work compared to maintenance therapy with…
- Trial name
- DREAM (NCT00265824)
- Testing
- bevacizumab, bevacizumab, erlotinib
- Where
- 47 sites in Austria, Canada and 1 more
- Volunteers
- 700 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Multi-Drug Resistant Hiv-1 Infection, HIV-1 Infection
A Trial of Anti-CD4 Antibody UB-421 in Combination With Optimized Background Antiretroviral Therapy in Patients With Multi-Drug Resistant HIV-1 Infection
Background: People with HIV usually take a combination of 2 or more anti-HIV drugs daily to help manage their infection. Sometimes, however, HIV becomes resistant to these drugs, and the infection cannot be treated.
- Trial name
- NCT05582694
- Testing
- UB-421
- Where
- United States
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hypertension, Vascular Diseases
Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT) in Subjects With Uncontrolled Hypertension
The purpose of the SPYRAL SWYFT sub-study is to evaluate whether renal denervation with the Symplicity Spyral system performed in the main and first order branch renal arteries yields a shorter procedure time and is as effective…
- Conditions
- Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases
- Trial name
- SWYFT (NCT07115953)
- Testing
- Symplicity Spyral™ multi-electrode renal denervation system
- Where
- 21 sites in Australia, Belgium and 7 more
- Volunteers
- 130 people
- Sponsor
- Medtronic Vascular
HIV
Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV
This Phase 3, single arm, multicenter study will evaluate the safety and effectiveness of ibalizumab in treatment-experienced patients infected with multi-drug resistant HIV-1.
- Trial name
- NCT02475629
- Testing
- ibalizumab, Optimized Background Regimen (OBR)
- Where
- 30 sites in United States, Puerto Rico and 1 more
- Volunteers
- 40 people
- Sponsor
- TaiMed Biologics Inc.
Liver Cirrhosis
Optimized Treatment and Regression of HBV-induced Early Cirrhosis
Patients with chronic hepatitis B histologically confirmed of early cirrhosis S4 (similar to metavir F4, Ishak 5/6) are randomly assigned in a 1:1 ratio.
- Trial name
- NCT01938820
- Testing
- entecavir, Thymosin-α
- Where
- 21 sites in China
- Volunteers
- 82 people
- Sponsor
- Beijing Friendship Hospital
HIV, Infectious
GRACE: A Study to Compare the Effectiveness, Safety and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race When Administered With Other Antiretroviral Medications in Human Immunodeficiency Virus (HIV) Positive Women and Men.
The purpose of this study is to evaluate any differences in the effectiveness, safety, and tolerability of PREZISTA (darunavir; DRV) 600 mg, administered with ritonavir (RTV) 100 mg twice a day on virologic response (defined as a…
- Trial name
- NCT00381303
- Testing
- darunavir, ritonavir
- Where
- 46 sites in United States, Canada and 1 more
- Volunteers
- 429 people
- Sponsor
- Tibotec, Inc
Liver Cirrhosis
PiCCO Guided Therapy in Liver Cirrhosis
Prospective comparison of standard therapy in liver cirrhosis versus standard therapy plus intensified hemodynamic monitoring using the PiCCO system.
- Trial name
- NCT00232427
- Testing
- Hemodynamic monitoring system PiCCO
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Heidelberg University
Cardiac Resynchronization Therapy
ECGi of SyncAV With MultiPoint Pacing
The objective of this clinical study was to evaluate the impact of Multipoint Pacing (MPP) and SyncAV programming on ventricular electrical activation time and activation sequence using noninvasive electrocardiographic imaging…
- Trial name
- NCT06444386
- Testing
- MPP + SyncAV
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Abbott Medical Devices
HIV Infections, Human Immunodeficiency Virus
Randomized, Double-Blind Study Comparing Dexelvucitabine (DFC) to Lamivudine (3TC) in Subjects With Resistance to NRTIs, PIs, and NNRTIs
The study will compare the safety and efficacy of an investigation nucleoside analog reverse transcriptase inhibitor (NRTI), dexelvucitabine (DFC), to an approved NRTI, lamivudine (3TC) in HIV treatment-experienced patients who…
- Trial name
- DECLARE (NCT00300573)
- Testing
- Dexelvucitabine
- Where
- 11 sites in United States, Puerto Rico
- Volunteers
- 250 people
- Sponsor
- Incyte Corporation
Major Depressive Disorder
Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)
This is a study that will test a predictive biomarker algorithm based on results from a previous study. The goal of this study is to integrate clinical, imaging, EEG, and molecular data across 8 sites to predict treatment outcome…
- Trial name
- CAN-BIND-17 (NCT05017311)
- Testing
- Escitalopram, Brexpiprazole
- Where
- 10 sites in Canada
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Nova Scotia Health Authority
Panic Disorder, Agoraphobia
Providing Tools for Effective Care and Treatment of Anxiety Disorders
PROTECT-AD is a cognitive behavioral treatment study involving highly qualified psychotherapeutic centers at seven German universities.
- Conditions
- Panic Disorder, Agoraphobia, Specific Phobias, Social Anxiety Disorder
- Trial name
- PROTECT-AD (NCT02605668)
- Testing
- Intensified psychological intervention, Standard intervention
- Where
- Germany
- Volunteers
- 726 people
- Sponsor
- Technische Universität Dresden
Two Different Treatment Methods
Research On the Optimized Treatment Method For Apatinib's Cure Of Advanced Gastric Cancer
The investigators hope that after this research, two different treatment methods' curative effects for advanced gastric cancer can be assessed.
- Trial name
- NCT03334591
- Testing
- Apatinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Anhui Provincial Hospital